



I never thought I could be myself again

Now I can

SEROQUEL is indicated for the treatment of acute manic episodes associated with bipolar I disorder and the treatment of schizophrenia. Patients should be periodically reassessed to determine the need for continued treatment.

Prescribing should be consistent with the need to minimize the risk of tardive dyskinesia, seizures, and orthostatic hypotension. A rare condition referred to as neuroleptic malignant syndrome (NMS) has been reported with this class of medications, including SEROQUEL.

There have been reports of diabetes mellitus and hyperglycemia-related adverse events associated with the use of atypical antipsychotics, including SEROQUEL.

The most commonly observed adverse events associated with the use of SEROQUEL in clinical trials were somnolence, dry mouth, dizziness, constipation, asthenia, abdominal pain, postural hypotension, pharyngitis, SGPT increase, dyspepsia, and weight gain.

 **Seroquel**[®]
quetiapine fumarate
25 mg, 100 mg, 200 mg & 300 mg tablets

AstraZeneca 

AstraZeneca Pharmaceuticals LP

To prevent medication errors, write **"SEROQUEL"** clearly on your Rx pad. Spell **"SEROQUEL"** clearly over the phone.

Please see Brief Summary of Prescribing Information on following page.

www.SEROQUEL.com

© 2004 AstraZeneca Pharmaceuticals LP. All rights reserved. SEROQUEL is a registered trademark of the AstraZeneca group of companies.

221563

8/04

<https://doi.org/10.1017/S1092852900009962> Published online by Cambridge University Press

Redefine Success